ArticleGynecologic oncology reports2026
Identifying and capitalizing on unique molecular alterations of mucinous ovarian carcinoma for the development of novel therapeutic strategies.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Mucinous ovarian carcinoma (MOC) is a rare histologic subtype of ovarian cancer. While prognosis of early stage disease is excellent, novel treatment options are needed for advanced stage and recurrent MOC, which are associated with poor oncologic outcomes. In this context, we aimed to investigate the genomic profile of MOC and characterize the prevalence of actionable genomic alterations. Methods: The American Association of Cancer Research Genomics Evidence of Neoplasia Information Exchange was accessed, and patients with mucinous ovarian, appendiceal and colorectal carcinoma were identified. Data from the OncoKB database, as provided by cBioPortal, were utilized to determine the presence of pathogenic gene alterations. When comparing the genomic profile of mucinous ovarian and colorectal or appendiceal carcinoma, to decrease the false discovery rate, a q-value of < 0.05 as derived from the Benjamini-Hochberg FDR correction procedure was deemed statistically significant. Results: A total of 148 patients with MOC contributing to 157 tumor samples were identified. The most commonly observed genetic alterations were in Conclusions: MOC has a distinct genomic profile with molecular vulnerabilities that can be exploited using novel targeted therapies. Participation of patients with MOC in molecularly driven early phase basket trials should be encouraged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.